(Q42956394)

English

Time to achieve blood pressure goal with a combination versus a conventional monotherapy approach in hypertensive patients with metabolic syndrome

scientific article published on January 2010

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Time to achieve blood pressure goal with a combination versus a conventional monotherapy approach in hypertensive patients with metabolic syndrome (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

metabolic syndrome

1 reference

based on heuristic

inferred from title

Giuseppe Derosa

6

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

author name string

Roberto Fogari

1

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Annalisa Zoppi

2

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Ilaria Ferrari

3

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Amedeo Mugellini

4

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Paola Preti

5

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

publication date

1 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Clinical and Experimental Hypertension

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

32

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

245-250

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Essential hypertension, metabolic disorders, and insulin resistance

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Metabolic syndrome and mortality in older adults: the Cardiovascular Health Study

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Metabolic syndrome and cardiovascular disease in older people: The cardiovascular health study.

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health Study

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Elevated systolic blood pressure and risk of cardiovascular and renal disease: overview of evidence from observational epidemiologic studies and randomized controlled trials

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient?

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

The metabolic syndrome in hypertension: diagnostic and therapeutic implications.

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Prevention and treatment of the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Relationship between insulin resistance and the renin-angiotensin system: analysis for patients with essential and renovascular hypertension

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

The management of hypertension in the overweight and obese patient: is weight reduction sufficient?

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Treating the metabolic syndrome using angiotensin receptor antagonists that selectively modulate peroxisome proliferator-activated receptor-gamma

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Effect of delapril/manidipine vs olmesartan/ hydrochlorothiazide combination on insulin sensitivity and fibrinogen in obese hypertensive patients

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Effects of the long-acting calcium channel blockers, amlodipine, manidipine and cilnidipine on steroid hormones and insulin resistance in hypertensive obese patients

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (A

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor bl

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Efficacy of the combination of amlodipine and valsartan in patients with hypertension uncontrolled with previous monotherapy: the Exforge in Failure after Single Therapy (EX-FAST) study

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Efficacy and safety of two treatment combinations of hypertension in very elderly patients

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

The importance of prompt blood pressure control

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

The role of therapeutic inertia and the use of fixed-dose combination therapy in the management of hypertension

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

What factors contribute to the inadequate control of elevated blood pressure?

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Restoration of nitric oxide availability after calcium antagonist treatment in essential hypertension

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Calcium Antagonists and Atherosclerosis Protection in Hypertension

1 reference

https://api.crossref.org/works/10.3109%2F10641960903265212

21 January 2018

Identifiers

10.3109/10641960903265212

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42956394&oldid=1975053693"